Barclays Remains Positive On Cerulean Pharma Despite Failed Renal Cancer Trial
August 30, 2016 at 14:19 PM EDT
Barclays remains Overweight on Cerulean Pharma Inc (NASDAQ: CERU), despite the failure of CRLX101 in renal cancer trial, as it thinks ...
